Higher-Dose Statins Linked to Moderate Increase in Diabetes Risk
By Kelly Young
Edited by Susan Sadoughi, MD , and Jaye Elizabeth Hefner, MD
Higher doses of statins are associated with greater risk for incident diabetes than lower doses, according to a BMJ study.
Using healthcare databases from Canada, the UK, and the US, researchers identified 137,000 patients who were prescribed statins after hospitalization for a major cardiovascular event. At 2 years, patients prescribed a higher-dose statin (rosuvastatin, 10 mg and up; atorvastatin, 20 mg and up; simvastatin, 40 mg and up) had a 15% higher rate of new diabetes diagnoses than lower-dose statin users. Incidence rates were highest in the first 4 months.
The authors conclude: "Clinicians should consider our study results when choosing between lower potency and higher potency statins in secondary prevention patients, perhaps bearing in mind that head-to-head randomized trials of higher potency versus lower potency statins have not shown a reduction in all-cause mortality or serious adverse events in secondary prevention patients with stable disease."
- See more at: http://www.jwatch.org/fw108892/2014/06/02/higher-dose-statins-linked-moderate-increase-diabetes#sthash.pAKrtJTt.dpuf